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high cardiovascular risk patients with suboptimally controlled hypercholesterolemia.
Methods This multicenter, phase 3, randomized (2:1 alirocumab vs placebo), double-blind, 52-week trial enrolled 316
patients with established coronary heart disease or coronary heart disease risk equivalents and hypercholesterolemia.
Alirocumab (75 mg every 2 weeks [Q2W]) or placebo Q2W was self-administered subcutaneously via 1 mL prefilled pen. The
alirocumab dose was increased to 150mgQ2W (also 1mL) at week 12 if week 8 low-density lipoprotein cholesterol (LDL-C) was
≥70 mg/dL. The primary efficacy end point was percent change in LDL-C from baseline to week 24 (intention-to-treat analysis).
Results At week 24, estimated mean (95% CI) changes in LDL-C from baseline were −48.2% (−52.0% to −44.4%) and
−2.3% (−7.6% to 3.1%) for alirocumab and placebo, respectively, an estimated mean (95% CI) difference of −45.9%
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Treatment-emergent adverse events were comparable between groups.
Conclusions Alirocumab treatment achieved a significantly greater reduction in LDL-C and allowed a greater proportion
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Volume 169, Number 6Statin therapy is currently the most effective approved
therapeutic intervention for lowering low-density lipo-
protein cholesterol (LDL-C), with reductions of up to 55%
depending on statin and dose.1,2 The magnitude of
clinical benefit attributable to statin therapy is directly
proportional to the level of pretreatment atherosclerotic
cardiovascular disease (ASCVD) risk and magnitude of
reduction in LDL-C.1-3 Currently, available nonstatin
lipid-lowering therapies (LLTs) have limited efficacy,
with bile acid resins, nicotinic acid, and fibrates
decreasing LDL-C by 10% to 20% on average and
ezetimibe-lowering LDL-C by 15% to 20% on average.4,5
Therefore, considerable interest exists in the develop-
ment of nonstatin therapies that more effectively reduce
LDL-C and other atherogenic lipid parameters in high-risk
patients on maximally tolerated doses of statin therapy
and for those who are statin intolerant.
Recent interest has focused on proprotein convertase
subtilisin/kexin type 9 (PCSK9) as a possible therapeutic
target. Alirocumab, a fully human monoclonal antibody to
PCSK9, has demonstrated significant reductions in LDL-C,
non–high-density lipoprotein cholesterol (non–HDL-C),
apolipoprotein B, and lipoprotein (a) when administered
in clinical trials to patients with hypercholesterolemia
despite statin therapy.6-9
ODYSSEY COMBO I (NCT01644175) is a randomized,
placebo-controlled, 52-week efficacy and safety study of
alirocumab administered every 2 weeks (Q2W) as add-on
therapy to stable, maximally tolerated daily statin therapy
(with or without other LLT) in patients at high ASCVD
risk.10 This study, and others within the ODYSSEY
program, uses a treat-to-target dosing strategy whereby
the alirocumab dose may be increased depending on
individual patient response.
Methods
This study was performed at 76 sites in the United
States in accordance with the ethical principles of the
Declaration of Helsinki and the International Conference
on Harmonization/Good Clinical Practice. The protocol
was reviewed and approved by the institutional review
board of each participating center, and all participants
provided written informed consent.
Full methods have been previously reported.10 Briefly,
male or female patients aged≥18 years could participate if
they had either (a) LDL-C≥70 mg/dL and established CVD
or (b) LDL-C ≥100 mg/dL with coronary heart disease
(CHD) risk equivalents (eg, diabetes mellitus with other
risk factors or chronic kidney disease). All patients were
receiving a stable, maximally tolerated statin dose (defined
as atorvastatin, 40-80 mg; rosuvastatin, 20-40 mg; or
simvastatin, 80 mg daily; or lower doses provided the
investigator had a documented reason for not using the
higher dose, eg, intolerance and local practice) with or
without other LLT (bile acid sequestrant, ezetimibe, niacin,or omega-3 ≥1000 mg/day with stable dose ≥4 weeks; or
fenofibrate with stable dose≥6 weeks before enrollment).
Exclusion criteria and definitions of CVD and CHD risk
equivalents are given in the online Appendix.
Eligible patients were randomized 2:1 to receive either
alirocumab 75-mg Q2W, self-administered subcuta-
neously via 1 mL prefilled pen, or a matching placebo.
Randomization was stratified by history of myocardial
infarction or ischemic stroke and intensity of concomi-
tant statin treatment (high intensity [atorvastatin, 40-80
mg daily; and rosuvastatin, 20-40 mg daily] or not high
intensity). If LDL-C level was ≥70 mg/dL at week 8,
alirocumab was increased in an automated and blinded
fashion without site or patient awareness to 150 mg
subcutaneously Q2W (also 1 mL) at the week 12 visit.
On-site patient assessments were scheduled at random-
ization and subsequently at weeks 4, 8, 12, 16, 24, 36, and
52. Injections were performed at home by the patient or a
designated caregiver. Training for the person performing
the injection was provided during screening. After
completion of double-blind treatment, patients were
followed up for an additional 8weeks off studymedication.
End points and assessments
The primary efficacy end point was the percent change
in LDL-C from baseline to week 24, analyzed using an
intention-to-treat (ITT) approach. Key secondary efficacy
end points included percent change in LDL-C from
baseline to week 24 (on-treatment analysis), percent
change in LDL-C at other defined time points, percent
changes in other lipid parameters, and proportion of
patients reaching LDL-C b70 mg/dL.10
All lipid analyses were performed by a central laboratory
(Medpace Reference Laboratories, Cincinnati, OH), and
LDL-C was calculated by the Friedewald formula.11 Low-
density lipoprotein cholesterol was also measured via β
quantification at randomization (week 0) and week 24
(and in cases where triglycerides exceeded 400 mg/dL
[4.52 mmol/L]). All other lipid parameters were measured
directly. Anti-alirocumab antibodies were assessed in all
patients regardless of treatment allocation at baseline
(week 0) as well as weeks 12, 24, 52, and 60 (follow-up).
Safety was assessed by adverse event (AE) reporting,
including adjudicated CV events, laboratory analyses
(including LDL-C b25 mg/dL on 2 consecutive measure-
ments ≥21 days apart), and vital signs measurement. The
safety population included all randomized patients who
received ≥1 dose or an incomplete injection. The
treatment-emergent AE (TEAE) period was defined as
the time from first to last double-blind dose of study
medication plus 70 days (10 weeks).Statistical methodology
Statistical methods were described previously.10 It was
estimated that 45 randomized patients (30 alirocumab; 15
Figure 1
Patient flow through the study. Abbreviation: CRF, case report form.
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June 2015placebo) would provide 95% power to detect a mean
percent change in LDL-C of ≥30% from baseline to 24
weeks with a 0.05 two-sided significance level, assuming
an SD of 25%. To accommodate a maximum estimated
subject drop-out rate of 30% (based on previous trials) at
52 weeks and to provide greater safety data to the
ODYSSEY Phase 3 program, the sample size was
increased to 306 patients.
The primary end point was assessed in the ITT
population, which included all randomized patients
regardless of treatment adherence with ≥1 available
LDL-C value both at baseline and at one of the planned
time points between weeks 4 and 24. A mixed effect
model with repeated measures was used to account for
missing data. All available postbaseline data from week 4
to week 52 were used regardless of status on or off
treatment. The model included fixed categorical effects
of treatment group, randomization strata, time point,
treatment-by-time point interaction, and strata-by-time
point interaction as well as the continuous fixed
covariates of baseline LDL-C value and baseline value-by-
time point interaction. This model provided baseline
adjusted least squares means estimates at week 24 for
both treatment groups with their corresponding 95% CIs.The difference between these estimates will be provided
with their corresponding 95% CI and P values.
A sensitivity analysis based on a pattern mixture model
was conducted to evaluate the impact of missing data on
the primary end point. In this approach, missing
calculated LDL-C values during the on-treatment period
were multiply imputed using a model assuming “missing
at random”; missing calculated LDL-C values during the
posttreatment period were multiply imputed using
random draws from a normal distribution where the
mean was equal to subject's own baseline value.
Secondary end points were analyzed in a predefined
order using a hierarchical testing procedure to control type
I error. These end points were analyzed with the same
methodology as for the primary end point, except
lipoprotein (a) and triglycerides, which were analyzed
using a multiple imputation approach for handling of
missing values followed by robust regression. The propor-
tion of patientswith LDL-C b70mg/dLwas analyzed using a
multiple imputation approach for handling of missing
values followed by logistic regression.
A prespecified on-treatment analysis was also conduc-
ted for the percent change in LDL-C from baseline to
week 24 and key secondary end points, using all available
Table I. Baseline characteristics (all randomized patients)
All patients on maximally
tolerated statin ± other LLT
Alirocumab Placebo P
(n = 209) (n = 107) vs placebo
Age, y, mean (SD) 63.0 (9.5) 63.0 (8.8) .77
Male, n (%) 131 (62.7) 77 (72.0) .11
Race, n (%) .61
White 170 (81.3) 88 (82.2)
Black or African American 34 (16.3) 17 (15.9)
Ethnicity, n (%) .44
Hispanic/Latino 25 (12.0) 9 (8.4)
BMI, kg/m2, mean (SD) 32.62 (6.30) 32.03 (7.07) .23
Any CV history/risk factors, n (%) 206 (98.6) 106 (99.1) .88
CHD history, n (%) 164 (78.5) 83 (77.6) .97
CHD risk equivalents, n (%)⁎ 85 (40.7) 51 (47.7) .28
Type 2 diabetes, n (%) 94 (45.0) 42 (39.3) .39
Lipid medication, n (%)
Any statin 208 (99.5) 107 (100) 1.00
High-dose statin use at screening† 129 (61.7) 69 (64.5) .71
Other LLT use 80 (38.3) 53 (49.5) .07
Ezetimibe use 15 (7.2) 11 (10.3) .46
Lipid parameters, mg/dL, mean (SD)
LDL-C (calculated)‡ 100.2 (29.5) 106.0 (35.3) .42
Median (Q1:Q3) 98.0 (81.0:114.0) 97.0 (86.0:120.0)
Minimum:maximum 33:240 61:256
LDL-C (measured)‡ 94.8 (29.3) 100.2 (34.4) .41
Non–HDL-C 130.0 (34.0) 133.4 (39.8) .72
Apo B 90.8 (21.4) 91.4 (24.1) .98
Lp(a)§ 31.0 (8.0:81.0) 38.0 (10.0:70.0) .70
Fasting TGs§ 130.0 (92.0:189.0) 123.0 (95.0:177.0) .57
HDL-C 48.3 (14.4) 48.8 (12.7) .46
Abbreviations: BMI, Body mass index; Apo, apolipoprotein; Lp(a), lipoprotein (a); TGs, triglycerides.
⁎Coronary heart disease risk equivalents were defined as ischemic stroke, peripheral artery disease, moderate chronic kidney disease, or diabetes (only if ≥2 risk factors present).
†High-dose statin: atorvastatin, 40 to 80 mg or rosuvastatin, 20 to 40 mg or simvastatin, 80 mg daily.
‡ Low-density lipoprotein cholesterol was calculated using the Friedewald formula and also measured by β quantification. The collection of measured LDL-C was not planned in the
initial protocol and was added in an amendment. Therefore, measured LDL-C values are available for fewer patients compared with calculated LDL-C values. At baseline, LDL-C was
measured for 138 alirocumab and 70 placebo patients.
§Median (Q1:Q3).
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weeks 4 to 52.
This study was funded by Sanofi and Regeneron
Pharmaceuticals, Inc; editorial assistance during manu-
script development was provided by Neil Venn and Rob
Campbell of Prime Medica Ltd, Knutsford, Cheshire,
United Kingdom, supported by Sanofi and Regeneron.
Responsibility for all opinions, conclusions, and interpre-
tation of data lies with the authors, who all approved the
final manuscript.Results
Of 640 patients screened for eligibility, 316 were
subsequently randomized to alirocumab (209) or placebo
(107) (Figure 1). The ITT population included 311
(98.4%) patients (5 patients had missing LDL-C levels
and were excluded from the ITT analysis); 309 patients
comprised the on-treatment population, and 314 patients
comprised the safety population. Baseline characteristicsof randomized patients (Table I) were similar with no
statistically significant differences between the treatment
groups. Over the 52-week double-blind period, adhe-
rence to study medication (receipt of ≥80% scheduled
injections) was similar between treatment groups (98%
alirocumab; 99% placebo). Based on week 8 LDL-C levels
≥70 mg/dL, 32 (16.8%) of 191 patients had their
alirocumab dose increased to 150 mg subcutaneously
Q2W at week 12 (among patients with ≥1 injection after
week 12).
Primary and secondary efficacy analyses
Estimated mean (95% CI) percent change from baseline
to week 24 in LDL-C was −48.2% (−52.0% to −44.4%) for
alirocumab and −2.3% (−7.6% to 3.1%) for placebo in the
ITT analysis and −50.7% (−54.4% to −47.0%) and −0.8%
(−5.9% to 4.3%), respectively, for the on-treatment
analysis (both P b .0001 for alirocumab vs placebo;
Table II, Figure 2, and online Supplementary Table I).
Measured LDL-C results (β quantification) were
Table II. Percent change in LDL-C and other lipid parameters (ITT analyses)
All patients on maximally
tolerated statin ± other LLT Alirocumab Placebo
Alirocumab vs placebo
Estimated mean difference % 95% CI P
ITT n = 205 n = 106
Baseline, mg/dL, mean (SD) 100.3 (29.7) 104.6 (32.3)
Minimum:maximum 33:240 61:243
Estimated mean (95% CI) change
from baseline to week 12 (%)
−46.3 1.1 −47.4 −53.6 to −41.3 b.0001
(−49.9 to −42.8) (−3.9 to 6.1)
Estimated mean (95% CI) change
from baseline at week 24 (%)
−48.2 −2.3
(−7.6 to 3.1)
−45.9 −52.5 to −39.3 b.0001
(−52.0 to −44.4)
Estimated mean (95% CI) percent change in other lipid parameters from baseline to week 24
ITT n = 205 n = 106
LDL-C (β quantification method)⁎ −46.1 −0.2 −45.9 −54.2 to −37.5 b.0001
(−50.9 to −41.4) (−7.1 to 6.6)
Apo B −36.7 −0.9 −35.8 −41.3 to −30.3 b.0001
(−39.9 to −33.5) (−5.4 to 3.5)
Non–HDL-C −39.1 −1.6 −37.5 −43.5 to −31.4 b.0001
(−42.6 to −35.6) (−6.6 to 3.3)
Total cholesterol −27.9 −2.9 −25.0 −29.3 to −20.7 b.0001
(−30.4 to −25.4) (−6.3 to 0.6)
Lp(a)† −20.5 −5.9 −14.6 −21.3 to −7.9 b.0001
(−24.4 to −16.6) (−11.3 to −0.5)
TGs† −6.0 −5.4 −0.6 −8.3 to 7.0 .8699
(−10.5 to −1.6) (−11.7 to 0.9)
HDL-C 3.5 −3.8 7.3 3.6 to 11.0 b.0001
(1.4 to 5.6) (−6.8 to −0.8)
Primary analyses were conducted using an ITT approach including all lipid data regardless of whether the patient was receiving study treatment.
⁎Sensitivity analysis; P value for descriptive purpose only.
†Combined estimate for adjusted mean (95% CI) shown for lipoprotein (a) and triglycerides.
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Results of a sensitivity analysis of the primary end
point were consistent with the ITT analysis (online
Supplementary Table I). Achieved LDL-C reduction over
time (Figure 3) demonstrates early (4weeks) and sustained
(52 weeks) reduction in LDL-C compared with placebo.
At week 12, before possible alirocumab dose increase
(all alirocumab patients were receiving 75-mg Q2W),
LDL-C reductions were 46.3% from baseline, comparable
with those at week 24 (Table II). The main baseline factor
predictive of a dose increase at week 12 was baseline
LDL-C level; distributions of baseline and week 24 LDL-C
levels are shown in online Supplementary Figure 1.
Among the 32 patients (16.8%) with alirocumab dose
increase at week 12 (based on LDL-C at week 8 ≥70 mg/
dL), achieved LDL-C was comparable at weeks 24, 36, and
52 with that observed among patients in whom no
dose incrementwas performed (week 8 LDL-C b70mg/dL) (
Figure 4). In patients with dose increase, LDL-Cwas reduced
by an additionalmean 22.8% (SD 27.1) atweek 24 compared
with week 12.
The relative proportions of patients achieving LDL-C
b70 mg/dL (b1.81 mmol/L) at week 24 in the ITT (75.0%)
and on-treatment (77.5%) analyses were significantlygreater with alirocumab than placebo (9.0% and 8.0%,
respectively; P b .0001) (Figure 5).
Significant reductions from baseline to week 24 after
therapy with alirocumab (P b .0001 vs placebo) were
observed in non–HDL-C (−39.1% [−42.6% to −35.6%]
vs −1.6% [−6.6% to 3.3%]), apolipoprotein B (−36.7%
[−39.9% to −33.5%] vs −0.9% [−5.4% to 3.5%]), total
cholesterol (−27.9% [−30.4% to −25.4%] vs −2.9%
[−6.3% to 0.6%]), and lipoprotein (a) (−20.5% [−24.4%
to −16.6%] vs −5.9% [−11.3% to −0.5%]) (Table II,
Figure 2, and online Supplementary Tables II-VIII); no
significant change was observed in triglyceride levels,
whereas a significant and directionally divergent
increase in HDL-C was observed after alirocumab of
3.5% (1.4%-5.6%) (vs −3.8% [−6.8% to −0.8%] placebo;
P b .0001) (Table II). Additional analysis of patients in
the highest quartile of baseline lipoprotein (a) (N79.5
mg/dL; 73 patients) revealed a mean percent change in
lipoprotein (a) from baseline to week 24 (alirocumab vs
placebo) similar to that observed in the overall study
population (−16.5% vs −14.6%, respectively). Patients
in the highest quartile of baseline triglyceride (N186
mg/dL; 75 patients) had adjusted mean percent changes
in triglyceride level from baseline to week 24 of −18.8%
Figure 3
Achieved calculated LDL-C levels over time with alirocumab and placebo on background maximally tolerated statin with or without other LLT (ITT
analysis). Baselines are described using mean; all other time points are estimated mean (95% CI). Values above and below data points indicate
estimated mean percent change from baseline and estimated mean achieved LDL-C levels.
Figure 2
End point analysis: percent reduction in LDL-C and other lipid parameters from baseline to week 24.
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Figure 4
Low-density lipoprotein cholesterol percent reduction in patients with and without alirocumab dose increase.
Figure 5
Proportion of patients reaching LDL-C b70 mg/dL (1.81 mmol/L) at
week 24. Multiple imputation method is used to address missing
values in the ITT and modified ITT populations. Combined estimate for
proportion of patients is obtained by averaging out all the imputed
proportions of patients reaching the level of interest. The P value is
statistically significant according to the fixed hierarchical approach
used to ensure a strong control of the overall type I error rate at the
0.05 level.
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There was no difference in response between placebo
and alirocumab-treated patients (combined estimate
for adjusted mean percent difference vs placebo of 4.8;
P = .6069).Subgroup analyses
Alirocumab produced 40% to 55% mean reduction in
LDL-C across prespecified subgroups including age,
gender, race, ethnicity, intensity of background statin
therapy, other LLT therapy (in addition to statin),
and history of myocardial infarction or ischemic stroke
(Figure 6). Greater variation in LDL-C reductions was
observed with placebo for some subgroups, particularly
those with small sample sizes (such as ethnicity
[Hispanic/Latino]), producing large CIs for the difference
in treatment effect for alirocumab versus placebo.
Although treatment effect was generally consistent across
subgroups, some heterogeneity in treatment effect
(P value for interaction b .05) was observed for patients
with other LLT therapy (in addition to statin) and those
with a history of myocardial infarction or ischemic stroke.
Safety measures
The incidences of TEAEs and serious TEAEs were
similar between treatment groups (Table III and online
Supplementary Table IX). Treatment-emergent AEs lead-
ing to death or study medication discontinuation were
uncommon in both groups (Table III). Local injection site
reactions, reported by 5.3% alirocumab-treated patients
(vs 2.8% placebo), were mild in severity and did not
prompt study medication discontinuation. Adverse
events related to potential general allergic reactions
occurred in 8.7% alirocumab versus 6.5% placebo
patients. There were few neurologic or neurocognitive
events. Laboratory assessments were similar between
groups and between alirocumab patients maintained on
the 75-mg dose or those increased to 150-mg Q2W.
Figure 6
Differences versus placebo for percent change from baseline in calculated LDL-C at week 24 by demographic characteristics and subgroup
analysis (ITT population). All patients on background of maximally tolerated statin ± other LLT. Abbreviations: CKD, chronic kidney disease;
MI, myocardial infarction. *High-intensity statin: atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily.
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Volume 169, Number 6Low-density lipoprotein cholesterol levels b25 mg/dL
(on 2 consecutive measurements ≥21 days apart)
were observed in 39 alirocumab-treated patients, of
whom 9 had LDL-C b15 mg/dL. The overall AE profile
appeared similar to those patients without such low
LDL-C levels (online Supplementary Table X). No
placebotreated patients reached LDL-C levels of b25 mg/
dL on 2 consecutive measurements.
Anti-alirocumab antibodies
A total of 13 alirocumab-treated patients (of 197
evaluable patients; 6.6%) had a positive response for the
anti-alirocumab antibody assay. Five patients randomized
to alirocumab (3/197; 1.5%) or placebo (2/99; 2.0%) had
preexisting immunoreactivity. Treatment-emergent and
low-titer antibody response was observed in 13 (6.6%) of
197 alirocumab-treated patients, in 7 of whom the
antibodies were transient and resolved despite continued
alirocumab treatment. Dose increase at week 12 did not
appear to contribute to the development of antibodies.
Of 8 patients with a positive response for the anti-
alirocumab antibody assay at week 24, 2 had a dose
increase in alirocumab to 150-mg Q2W at week 12; in both
of these patients, antibodieswere transient and resolved by
week 52. Of the 13 alirocumab-treated patients positive inthe anti-alirocumab antibody assay, 4 were positive for
alirocumab-neutralizing antibodies; each of these resolved
(became negative) within 24 weeks. The median time to
detection of antibodies to alirocumab was 12 weeks, and
no specific clinical events were observed in antibody-
positive patients. The presence of anti-alirocumab
antibodies had no observed effect on LDL-C–lowering
efficacy (online Supplementary Figure 2) or safety.Discussion
Self-administered alirocumab versus placebo added to
maximally tolerated statin therapy with or without other
LLT was associated with (a) a 48% reduction from
baseline (pretreatment) to 24 weeks in LDL-C, corre-
sponding to achieved estimated mean LDL-C levels of
51 mg/dL (vs 98 mg/dL with placebo); (b) significant
reductions in non–HDL-C, total cholesterol, apolipopro-
tein B, and lipoprotein (a); and (c) a greater portion of
patients who achieved LDL-C b70 mg/dL (75% vs 9%).
These efficacy data complement clinical trial results using
alirocumab as monotherapy8 and are consistent with
previous phase 2 trial results.6,7,9
COMBO I used a treat-to-target level dosing strategy
based on individual patient responses to alirocumab
Table III. Adverse events and safety laboratory values (safety population)
n (%) of patients Alirocumab Placebo
All patients on maximally tolerated statin ± other LLT (n = 207) (n = 107)
TEAEs 157 (75.8) 81 (75.7)
Treatment-emergent SAEs 26 (12.6) 14 (13.1)
TEAE leading to death 2 (1.0) 3 (2.8)
TEAEs leading to discontinuation 13 (6.3) 8 (7.5)
TEAEs by preferred term occurring in ≥5% of patients in either group
Upper respiratory tract infection 16 (7.7) 11 (10.3)
Arthralgia 8 (3.9) 8 (7.5)
Nasopharyngitis 15 (7.2) 5 (4.7)
Urinary tract infection 13 (6.3) 4 (3.7)
Dizziness 11 (5.3) 6 (5.6)
Noncardiac chest pain 2 (1.0) 7 (6.5)
Sinusitis 11 (5.3) 4 (3.7)
Injection site reaction 11 (5.3) 3 (2.8)
Safety terms of interest⁎
Local injection site reactions 11 (5.3) 3 (2.8)
Potential general allergic reaction events 18 (8.7) 7 (6.5)
Neurologic events 5 (2.4) 2 (1.9)
Neurocognitive disorders 0 (0) 1 (0.9)
CV TEAEs confirmed by adjudication
Any patients with treatment-emergent CV events confirmed by adjudication† 6(2.9) 3 (2.8)
CHD death (including undetermined cause) 1(0.5) 1 (0.9)
Nonfatal myocardial infarction 1(0.5) 1 (0.9)
Fatal and nonfatal ischemic stroke (including stroke not otherwise specified) 2 (1.0) 0
Unstable angina requiring hospitalization 0 0
Congestive heart failure requiring hospitalization 0 1 (0.9)
Ischemia-driven coronary revascularization procedure 3 (1.4) 1 (0.9)
Abbreviations: SAEs, Serious AEs.
⁎Neurocognitive events were selected using a company Medical Dictionary for Regulatory Activities query based on the following 5 high-level group terms: deliria (including
confusion), cognitive and attention disorders and disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders.
†One patient in the placebo group and 1 patient in the alirocumab group each experienced 2 events that were positively adjudicated: nonfatal myocardial infarction and ischemia-
driven coronary revascularization procedure.
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week 12) high CV risk patients on background statin
therapy achieved an LDL-C b70 mg/dL on the 75-mg Q2W
alirocumab dose regimen at week 8 and did not need
dose increase to 150-mg Q2W. These patients demon-
strated consistent efficacy over time. Low-density lipo-
protein cholesterol reduction for weeks 24 to 52 was
comparable among those patients in whom alirocumab
dose was increased to 150 mg at week 12 (LDL-C
≥70 mg/dL at week 8) and those who remained on
alirocumab 75 mg throughout the duration of the study.
In this study, increase in alirocumab dose produced an
additional 22.8% reduction in LDL-C, providing rationale
for initiation of alirocumab therapy using the 75-mg dose
with the potential to increase to 150 mg if further LDL-C
reduction is required.
When administered in conjunction with maximally
tolerated statin with or without additional LLT, alirocu-
mab treatment appeared to be generally well tolerated
over 52 weeks of therapy, with incidences of TEAEs and
serious AEs largely comparable with those observed on
placebo. Injection site reactions occurred more frequentlyin alirocumab-treated patients versus placebo; however,
consistent with previous reports,6-9 they were mostly
graded mild in severity. Development of anti-alirocumab
antibodies was observed in 6.6% of evaluable alirocumab-
treated patients; however, these were transient
(despite continued treatment) in almost two-thirds of
cases, and there was no association between develop-
ment of antibodies and clinical sequelae or LDL-C
lowering. Overall safety findings were similar to other
alirocumab studies reported thus far6-9 and for other
PCSK9 inhibitors.12
Although sufficiently powered to detect the primary
end point of LDL-C reduction from baseline to week 24,
this study remains relatively small with respect to
subgroup analyses. Analysis using pooled data from the
multinational ODYSSEY phase 3 program will provide
more comprehensive assessment in terms of consistency
of alirocumab treatment effect across subgroups (includ-
ing in patients with LDL-C b25 mg/dL) and patient
populations. COMBO I provided further demonstration of
the LDL-C–lowering efficacy and safety of alirocumab in a
high CV risk population; however, clinical outcomes data
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Volume 169, Number 6(currently being collected in the OUTCOMES trial
NCT01663402) are required to corroborate any potential
benefit with respect to CV events.
In patients at high ASCVD risk with hypercholestero-
lemia despite treatment with maximally tolerated statin
(with or without other LLT), alirocumab reduced LDL-C
through 52 weeks of treatment and was well tolerated.
Alirocumab 75-mg Q2W was sufficient for a majority of
patients to achieve LDL-C b70 mg/dL without the need
for subsequent dose increase to 150 mg. These findings
provide support for initiating alirocumab therapy at
75-mg Q2W in patients on maximized standard of care
who have suboptimally controlled hypercholesterolemia,
with dose increase to 150-mg Q2W in those patients not
achieving LDL-C lower than 70 mg/dL.
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Key inclusion/exclusion criteria
Full details of the study design have been published
previously.10The definitions of CHD included acute myocardial
infarction, silent myocardial infarction, unstable angina,
coronary revascularization, or clinically significant CHD
diagnosed by invasive or noninvasive testing. Coronary
heart disease risk equivalents included peripheral arterial
disease, ischemic stroke, chronic kidney disease (esti-
mated glomerular filtration rate ≥30 to b60 mL/min per
1.73 m2 for ≥3 months), or diabetes mellitus in
combination with ≥2 additional risk factors (hyperten-
sion, ankle-brachial index ≤0.90, microalbuminuria or
macroalbuminuria, dipstick urinalysis with N2+ protein,
retinopathy, or family history of premature CHD [b55
years in father/brother or b65 years in mother/sister]).
Specific protocol-defined exclusion criteria included
known hypersensitivity to monoclonal antibody thera-
peutics, women of childbearing potential with no
effective contraceptive method, uncontrolled diabetes
with hemoglobin A1C N8.5% or diagnosed within 3
months, clinically significant uncontrolled endocrine
disease known to influence serum lipids or lipoproteins,
blood pressure N160/100 mm Hg, major CV event within
3 months, New York Heart Association class III or IV, heart
failure within 12 months, fasting serum triglycerides
N400 mg/dL (4.52 mmol/L), thyroid-stimulating hormone
either below or above the upper limit of normal, alanine
aminotransferase, aspartate aminotransferase, or creatine
phosphokinase N3× upper limit of normal.
Additional statistical methodology
A mixed effect model with repeated measures was used
to account for missing data and included fixed categorical
effects of treatment group, randomized strata, time point,
treatment-by-time point interaction, and strata-by-time
point interaction as well as the continuous fixed covariates
of baseline LDL-C value and baseline value-bytime point
interaction. A sensitivity analysis based on a pattern
mixture model was conducted to evaluate the impact of
missing data on the primary end point; in this approach,
missing calculated LDL-C values during the on-treatment
period were multiply imputed using a model assuming
“missing at random”; missing calculated LDL-C values
during the posttreatment period were multiply imputed
using random draws from a normal distribution where the
mean was equal to subject's own baseline value.
Secondary end pointswere analyzed in a predefined order
using a hierarchical testing procedure to control type I error.
Secondary lipid end points were analyzed as for the primary
end point, except lipoprotein (a) and triglycerides, which
were analyzed using a multiple imputation approach for
handling of missing values followed by robust regression.The proportion of patients with LDL-C b70 mg/dL was
analyzed by logistic regression.
A prespecified on-treatment analysis was also conduct-
ed for the percent change in LDL-C from baseline to week
24 and key secondary end points, using all available
on-treatment measurements at planned time points from
weeks 4 to 52.
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Supplementary Figure 1
Distribution of absolute LDL-C levels at baseline and week 24 for (A) all alirocumab-treated patients and (B) all placebo-treated patients (on
treatment analyses). C and D, show the distribution within the alirocumab group for (C) alirocumab-treated patients who remained on a dose of
75-mg Q2W through the study and (D) alirocumab-treated patients who received a dose increase to 150-mg Q2W at week 12 if their LDL-C was
≥70 mg/dL at week 8.
Supplementary Figure 2
Percent reduction in LDL-C from baseline to week 24 by anti-alirocumab antibody status.
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Supplementary Table I. Percent change from baseline in calculated LDL-C: on-treatment and sensitivity (pattern mixture model—ITT
analysis—randomized population) analyses
All patients on maximally
tolerated statin ± other LLT Alirocumab Placebo
Alirocumab vs placebo
Estimated mean difference
95% CI P%
On-treatment analysis n = 204 n = 105
Baseline, mg/dL, mean (SD) 99.8 (29.0) 105.0 (32.2)
Minimum:maximum 33:240 61:243
Estimated mean (95% CI) change
from baseline to week 12 (%)
−47.6 1.7 −49.3 −55.3 to b.0001
(−51.1 to −44.1) (−3.1 to 6.5) −43.3
Estimated mean (95% CI) change
from baseline at week 24 (%)
−50.7 −0.8 −49.9 −56.2 to b.0001
(−54.4 to −47.0) (−5.9 to 4.3) −43.6
Sensitivity analysis n = 205 n = 106
Baseline, mg/dL 100.3 (29.7) 104.6 (32.3)
Min:max 33:240 61:243
Combined estimate for mean (95% CI)
change from baseline at week 24 (%)
−44.2 −1.5 −42.7 (−49.9 to −35.4) b.0001
(−48.4 to −40.1) (−7.4 to 4.4)
Values are mean (SD) unless stated.
Only patients who were receiving study treatment were included in the on-treatment analysis (modified ITT).
The sensitivity analysis has been conducted to further evaluate the impact of missing data on the primary end point: in this approach, missing calculated LDL-C values during the
“on-treatment” period were multiply imputed using a model assuming missing at random, and missing calculated LDL-C values during the posttreatment period were multiply imputed
using random draws from a normal distribution, with mean equal to subject's own baseline value.
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Supplementary Table II. Calculated LDL-C over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Calculated LDL-C
(mg/dL) Value
Change from
baseline
Percent change
from baseline Value
Change from
baseline
Percent change
from baseline
Baseline
No. of patients 205 NA NA 106 NA NA
No. of missing data – –
Mean (SD) 100.3 (29.7) 104.6 (32.3)
Week 4
No. of patients 198 198 198 102 102 102
No. of missing data 7 7 7 4 4 4
Mean (SD) 49.8 (31.1) −50.2 (25.4) −50.9 (23.6) 99.2 (31.7) −4.7 (28.4) −1.8 (25.6)
Week 8
No. of patients 196 196 196 101 101 101
No. of missing data 9 9 9 5 5 5
Mean (SD) 47.2 (26.6) −52.5 (28.5) −51.8 (26.1) 101.7 (31.6) −3.0 (23.4) −0.8 (21.1)
Week 12
No. of patients 193 193 193 99 99 99
No. of missing data 12 12 12 7 7 7
Mean (SD) 53.8 (31.4) −46.1 (28.2) −46.5 (26.0) 104.7 (41.5) −0.2 (30.7) 1.3 (25.3)
Week 16
No. of patients 185 185 185 96 96 96
No. of missing data 20 20 20 10 10 10
Mean (SD) 47.7 (28.4) −52.2 (31.2) −51.4 (26.4) 102.5 (33.0) −3.0 (28.2) 0.2 (24.8)
Week 24
No. of patients 189 189 189 97 97 97
No. of missing data 16 16 16 9 9 9
Mean (SD) 50.4 (28.6) −49.3 (33.4) −47.9 (29.1) 100.0 (35.2) −5.3 (30.2) −2.5 (24.9)
Week 36
No. of patients 168 168 168 90 90 90
No. of missing data 37 37 37 16 16 16
Mean (SD) 52.0 (32.7) −46.4 (35.5) −44.9 (37.6) 97.7 (33.3) −5.7 (21.4) −4.6 (20.0)
Week 52
No. of patients 167 167 167 79 79 79
No. of missing data 38 38 38 27 27 27
Mean (SD) 56.6 (37.1) −43.8 (37.3) −42.4 (35.2) 98.8 (25.7) −1.4 (25.8) 1.4 (27.7)
Abbreviation: NA, Not applicable.
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Supplementary Table III. Apolipoprotein B over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Apolipoprotein B (mg/dL) Value Percent change from baseline Value Percent change from baseline
Baseline
No. of patients 189 NA 100 NA
No. of missing data 16 6
Mean (SD) 90.8 (21.5) 90.4 (21.9)
Week 12
No. of patients 195 181 98 93
No. of missing data 10 24 8 13
Mean (SD) 59.6 (24.4) −34.7 (22.1) 93.4 (30.3) 3.5 (22.0)
Week 24
No. of patients 192 181 97 92
No. of missing data 13 24 9 14
Mean (SD) 56.3 (21.5) −36.5 (23.2) 89.6 (24.0) −1.1 (21.4)
Week 52
No. of patients 176 167 81 76
No. of missing data 29 38 25 30
Mean (SD) 63.0 (27.3) −30.6 (29.4) 90.6 (19.7) 4.3 (23.1)
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Supplementary Table IV. Non–HDL-C over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Non-HDL cholesterol (mg/dL) Value Percent change from baseline Value Percent change from baseline
Baseline
No. of patients 205 NA 106 NA
No. of missing data – –
Mean (SD) 130.1 (34.3) 131.7 (36.3)
Week 4
No. of patients 200 200 102 102
No. of missing data 5 5 4 4
Mean (SD) 76.5 (36.4) −41.7 (19.9) 125.2 (36.5) −2.5 (21.3)
Week 8
No. of patients 199 199 102 102
No. of missing data 6 6 4 4
Mean (SD) 72.1 (29.2) −43.4 (21.0) 129.9 (35.3) −0.1 (18.4)
Week 12
No. of patients 196 196 99 99
No. of missing data 9 9 7 7
Mean (SD) 81.1 (42.2) −37.3 (28.0) 134.2 (44.2) 2.8 (21.0)
Week 16
No. of patients 188 188 98 98
No. of missing data 17 17 8 8
Mean (SD) 73.1 (34.3) −42.7 (24.0) 130.4 (37.3) 0.2 (21.8)
Week 24
No. of patients 192 192 97 97
No. of missing data 13 13 9 9
Mean (SD) 77.3 (34.0) −39.0 (25.8) 128.0 (41.7) −1.6 (25.1)
Week 36
No. of patients 177 177 90 90
No. of missing data 28 28 16 16
Mean (SD) 82.2 (41.3) −35.2 (28.3) 125.9 (37.1) −2.4 (18.1)
Week 52
No. of patients 175 175 81 81
No. of missing data 30 30 25 25
Mean (SD) 85.4 (42.8) −32.5 (32.8) 128.8 (29.6) 3.4 (25.0)
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Supplementary Table V. Total cholesterol over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Cholesterol (mg/dL) Value Percent change from baseline Value Percent change from baseline
Baseline
No. of patients 205 NA 106 NA
No. of missing data – –
Mean (SD) 178.5 (36.0) 180.7 (36.3)
Week 4
No. of patients 200 200 102 102
No. of missing data 5 5 4 4
Mean (SD) 126.6 (37.7) −29.1 (14.7) 173.3 (37.4) −2.6 (17.0)
Week 8
No. of patients 199 199 102 102
No. of missing data 6 6 4 4
Mean (SD) 122.0 (32.0) −30.7 (15.8) 177.1 (35.6) −1.1 (13.2)
Week 12
No. of patients 196 196 99 99
No. of missing data 9 9 7 7
Mean (SD) 132.1 (43.2) −25.2 (21.5) 181.3 (43.2) 0.9 (16.2)
Week 16
No. of patients 188 188 98 98
No. of missing data 17 17 8 8
Mean (SD) 123.0 (34.8) −30.0 (17.8) 177.4 (38.1) −1.3 (16.6)
Week 24
No. of patients 192 192 97 97
No. of missing data 13 13 9 9
Mean (SD) 126.5 (34.0) −27.7 (18.4) 174.4 (40.9) −3.1 (18.7)
Week 36
No. of patients 177 177 90 90
No. of missing data 28 28 16 16
Mean (SD) 130.3 (40.3) −25.2 (20.9) 172.3 (35.9) −3.4 (13.5)
Week 52
No. of patients 175 175 81 81
No. of missing data 30 30 25 25
Mean (SD) 136.2 (44.1) −22.4 (23.4) 175.1 (30.3) 0.5 (16.1)
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Supplementary Table VI. Lipoprotein (a) over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Lipoprotein (a) (mg/dL) Value Percent change from baseline Value Percent change from baseline
Baseline
No. of patients 189 NA 100 NA
No. of missing data 16 6
Median 31.0 38.0
Q1:Q3 8.0:81.0 10.0:71.0
Min:max 2:248 2:184
Week 12
No. of patients 195 181 98 93
No. of missing data 10 24 8 13
Median 26.0 −16.7 35.0 0.0
Q1:Q3 5.0:71.0 −35.4:0.0 11.0:75.0 −13.7:14.3
Min:max 2:206 −85:771 2:254 −60:600
Week 24
No. of patients 192 181 97 92
No. of missing data 13 24 9 14
Median 20.0 −20.8 30.0 −5.4
Q1:Q3 6.0:65.0 −37.8:0.0 10.0:67.0 −18.2:5.9
Min:max 2:197 −85:657 2:243 −63:67
Week 52
No. of patients 176 167 81 76
No. of missing data 29 38 25 30
Median 20.0 −25.0 26.0 −14.8
Q1:Q3 5.0:60.5 −45.6:0.0 9.0:69.0 −25.8:0.0
Min:max 2:189 −85:543 2:167 −65:100
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Supplementary Table VII. TGs over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
Fasting triglycerides (mg/dL) Value
Percent change
from baseline Value
Percent change
from baseline
Baseline
No. of patients 205 NA 105 NA
No. of missing data – 1
Median 130.0 123.0
Q1:Q3 92.0:189.0 95.0:175.0
Min:max 35:999 52:431
Week 4
No. of patients 197 197 101 100
No. of missing data 8 8 5 6
Median 118.0 −11.7 122.0 −5.8
Q1:Q3 85.0:157.0 −28.1:7.0 89.0:160.0 −17.3:16.8
Min:max 34:438 −72:125 48:365 −68:84
Week 8
No. of patients 197 197 101 101
No. of missing data 8 8 5 5
Median 113.0 −13.6 130.0 0.0
Q1:Q3 84.0:145.0 −30.6:7.7 87.0:171.0 −18.8:22.6
Min:max 33:508 −58:127 41:442 −53:131
Week 12
No. of patients 196 196 98 98
No. of missing data 9 9 8 8
Median 110.5 −14.1 129.0 3.5
Q1:Q3 84.5:159.0 −30.8:11.2 102.0:184.0 −11.1:23.4
Min:max 30:1247 −77:277 47:384 −46:172
Week 16
No. of patients 186 186 98 98
No. of missing data 19 19 8 8
Median 116.0 −12.6 132.0 2.7
Q1:Q3 82.0:151.0 −29.2:9.8 95.0:173.0 −13.8:23.2
Min:max 36:627 −69:160 53:427 −57:110
Week 24
No. of patients 191 191 96 96
No. of missing data 14 14 10 10
Median 116.0 −8.4 113.0 −6.4
Q1:Q3 84.0:157.0 −27.1:17.8 87.5:154.0 −20.2:22.9
Min:max 36:511 −66:287 46:669 −69:142
Week 36
No. of patients 176 176 88 88
No. of missing data 29 29 18 18
Median 123.5 −4.5 125.5 −1.0
Q1:Q3 89.0:176.0 −24.7:26.2 96.5:173.0 −16.1:20.3
Min:max 35:1776 −58:238 53:365 −43:113
Week 52
No. of patients 175 175 80 80
No. of missing data 30 30 26 26
Median 126.0 −3.3 129.5 5.0
Q1:Q3 95.0:171.0 −25.3:26.7 96.5:174.5 −12.4:33.4
Min:max 28:683 −70:413 65:476 −67:258
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Supplementary Table VIII. High-density lipoprotein cholesterol over time (raw data, ITT analysis)
Alirocumab Placebo
(n = 205) (n = 106)
HDL cholesterol (mg/dL) Value
Percent change
from baseline
Value Percent change
from baseline
Baseline
No. of patients 205 NA 106 NA
No. of missing data – –
Mean (SD) 48.3 (14.5) 48.8 (12.8)
Week 4
No. of patients 200 200 102 102
No. of missing data 5 5 4 4
Mean (SD) 49.9 (14.1) 4.3 (12.9) 48.1 (12.0) −0.8 (11.4)
Week 8
No. of patients 199 199 102 102
No. of missing data 6 6 4 4
Mean (SD) 49.9 (13.7) 4.8 (14.4) 47.2 (11.5) −1.3 (11.9)
Week 12
No. of patients 196 196 99 99
No. of missing data 9 9 7 7
Mean (SD) 51.0 (15.0) 6.6 (15.8) 47.1 (12.9) −2.8 (13.4)
Week 16
No. of patients 188 188 98 98
No. of missing data 17 17 8 8
Mean (SD) 49.9 (13.8) 4.0 (14.4) 46.9 (13.7) −3.0 (15.7)
Week 24
No. of patients 192 192 97 97
No. of missing data 13 13 9 9
Mean (SD) 49.2 (13.4) 3.7 (16.3) 46.4 (12.5) −4.3 (16.4)
Week 36
No. of patients 177 177 90 90
No. of missing data 28 28 16 16
Mean (SD) 48.1 (13.8) 1.6 (16.2) 46.4 (11.3) −4.7 (14.1)
Week 52
No. of patients 175 175 81 81
No. of missing data 30 30 25 25
Mean (SD) 50.9 (13.5) 6.7 (18.8) 46.3 (12.3) −3.9 (16.4)
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Supplementary Table IX. Treatment-emergent AEs occurring in ≥2% of patients in either group (safety population)
n (%) of patients Alirocumab Placebo
All patients on maximally tolerated statin ± other LLT (n = 207) (n = 107)
TEAEs occurring in ≥2% of patients in either group
Infections and infestations 77 (37.2) 29 (27.1)
Upper respiratory tract infection 16 (7.7) 11 (10.3)
Nasopharyngitis 15 (7.2) 5 (4.7)
Urinary tract infection 13 (6.3) 4 (3.7)
Sinusitis 11 (5.3) 4 (3.7)
Bronchitis 10 (4.8) 5 (4.7)
Influenza 6 (2.9) 0
Herpes zoster 2 (1.0) 3 (2.8)
Musculoskeletal and connective tissue disorders 49 (23.7) 23 (21.5)
Arthralgia 8 (3.9) 8 (7.5)
Osteoarthritis 8 (3.9) 5 (4.7)
Pain in extremity 8 (3.9) 3 (2.8)
Myalgia 7 (3.4) 4 (3.7)
Back pain 5 (2.4) 4 (3.7)
Injury, poisoning, and procedural complications 29 (14.0) 22 (20.6)
Contusion 7 (3.4) 5 (4.7)
Fall 7 (3.4) 5 (4.7)
Gastrointestinal disorders 39 (18.8) 17 (15.9)
Diarrhea 8 (3.9) 3 (2.8)
Nausea 8 (3.9) 0
Constipation 6 (2.9) 3 (2.8)
Gastroesophageal reflux disease 3 (1.4) 4 (3.7)
Nervous system disorders 24 (11.6) 17 (15.9)
Dizziness 11 (5.3) 6 (5.6)
Headache 7 (3.4) 3 (2.8)
General disorders and administration-site conditions 26 (12.6) 16 (15.0)
Injection-site reaction 11 (5.3) 3 (2.8)
Edema peripheral 5 (2.4) 2 (1.9)
Noncardiac chest pain 2 (1.0) 7 (6.5)
Respiratory, thoracic, and mediastinal disorders 28 (13.5) 14 (13.1)
Asthma 5 (2.4) 0
Cough 5 (2.4) 4 (3.7)
Vascular disorders 14 (6.8) 6 (5.6)
Hypertension 10 (4.8) 2 (1.9)
Psychiatric disorders 12 (5.8) 5 (4.7)
Depression 5 (2.4) 2 (1.9)
Blood and lymphatic system disorders 5 (2.4) 3 (2.8)
Anemia 5 (2.4) 2 (1.9)
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Supplementary Table X. Incidence of TEAEs including alirocumab-treated patients with 2 consecutive LDL-C values ≤25 mg/dL
(safety population)
n (%) of patients Alirocumab
Alirocumab
Placebo2 consecutive
All patients on maximally
tolerated statin ± other LLT
(n = 207) LDL-C ≤25 mg/dL (n = 107)
(n = 39)
TEAEs (any class) 157 (75.8) 29 (74.4) 81 (75.7)
TEAEs by preferred term occurring in ≥5%
of patients in any group
Infections and infestations 77 (37.2) 11 (28.2) 29 (27.1)
Upper respiratory tract infection 16 (7.7) 1 (2.6) 11 (10.3)
Nasopharyngitis 15 (7.2) 2 (5.1) 5 (4.7)
Urinary tract infection 13 (6.3) 2 (5.1) 4 (3.7)
Sinusitis 11 (5.3) 1 (2.6) 4 (3.7)
Bronchitis 10 (4.8) 3 (7.7) 5 (4.7)
Musculoskeletal and connective tissue disorders 49 (23.7) 12 (30.8) 23 (21.5)
Arthralgia 8 (3.9) 2 (5.1) 8 (7.5)
Osteoarthritis 8 (3.9) 2 (5.1) 5 (4.7)
Myalgia 7 (3.4) 3 (7.7) 4 (3.7)
Intervertebral disc protrusion 2 (1.0) 2 (5.1) 0 (0)
Gastrointestinal disorders 39 (18.8) 4 (10.3) 17 (15.9)
Nausea 8 (3.9) 2 (5.1) 0 (0)
General disorders and administration-site conditions 26 (12.6) 3 (7.7) 16 (15.0)
Injection-site reaction 11 (5.3) 2 (5.1) 3 (2.8)
Noncardiac chest pain 2 (1.0) 1 (2.6) 7 (6.5)
Injury, poisoning, and procedural complications 29 (14.0) 5 (12.8) 22 (20.6)
Contusion 7 (3.4) 2 (5.1) 5 (4.7)
Fall 7 (3.4) 2 (5.1) 5 (4.7)
Nervous system disorders 24 (11.6) 1 (2.6) 17 (15.9)
Dizziness 11 (5.3) 1 (2.6) 6 (5.6)
Ear and labyrinth disorders 4 (1.9) 3 (7.7) 4 (3.7)
Cerumen impaction 2 (1.0) 2 (5.1) 0 (0)
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